1445179-97-4
1445179-97-4 structure
| Name | D-JNKI-1 |
|---|---|
| Synonyms | 2K30142185 |
| Description | D-JNKI-1 is a specific inhibitor of JNK, and strongly interferes with JNK activation. |
|---|---|
| Related Catalog | |
| Target |
JNK |
| In Vitro | D-JNKI-1 (1 μM-1 mM) treatment prevents apoptosis and loss of neomycin-exposed hair cells[1]. |
| In Vivo | D-JNKI-1 (10 μM) prevents nearly all hair cell death and permanent hearing loss induced by neomycin ototoxicity in the scala tympani of the guinea pig cochlea. Local delivery of D-JNKI-1 also prevents acoustic trauma-induced permanent hearing loss in a dose-dependent manner[1]. D-JNKI-1 (0.3 mg/kg, i.p.) reverses these pathological events in the brain mitochondria of the rat and almost completely abolishes cytochrome c release and PARP cleavage[2]. D-JNKI-1 (1 μg/kg, s.c.) results in a significant decrease in the disease activity index, and reduces the expression of CD4+ and CD8+ cells in mice[3]. |
| Animal Admin | D-JNKI-1 is dissolved in a 0.9% sodium chloride solution for subcutaneous application. Each group (the 1.0% DSS group and the 1.5% DSS group) is randomly subdivided into an intervention group (n = 15) and a control group (n = 15). The mice in the intervention group receive three subcutaneous nuchal administrations of 1 μg/kg D-JNKI-1 on days 2, 12, and 22. The mice in the control group receive physiological saline subcutaneously as a negative control at the same time points in a comparable stress situation. |
| References |
| Molecular Formula | C164H286N66O40 |
|---|---|
| Storage condition | -20°C |